{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:47:19Z","timestamp":1790459239817,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Centre Hospitalier Universitaire de Besan\u00e7on"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3566-0","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T13:48:22Z","timestamp":1503668902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-7119","authenticated-orcid":false,"given":"Stefano","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Jary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Buecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Peiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Baba-Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"El Hajbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Desrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Parzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Zoubir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher Ben","family":"Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"De La Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar","family":"Bennouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Gornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Jacquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"key":"3566_CR1","unstructured":"National Cancer Institute. SEER cancer statistics factsheets: anal cancer. http:\/\/seer.cancer.gov\/statfacts\/html\/anus.html . Accessed 7 May 2016."},{"key":"3566_CR2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.2012.45.2524","volume":"31","author":"RA Nelson","year":"2013","unstructured":"Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL. Changing patterns of Anal Canal carcinoma in the United States. J Clin Oncol. 2013;31:1569\u201375.","journal-title":"J Clin Oncol"},{"key":"3566_CR3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11912-016-0503-3","volume":"18","author":"DR Julie","year":"2016","unstructured":"Julie DR, Goodman KA. Advances in the Management of Anal Cancer. Curr Oncol Rep. 2016;18:20\u201312.","journal-title":"Curr Oncol Rep"},{"key":"3566_CR4","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.3748\/wjg.v21.i8.2294","volume":"21","author":"M Ghosn","year":"2015","unstructured":"Ghosn M. Anal cancer treatment: current status and future perspectives. WJG. 2015;21:2294\u201310.","journal-title":"WJG"},{"key":"3566_CR5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol. 1997;15:2040\u20139.","journal-title":"J Clin Oncol"},{"key":"3566_CR6","doi-asserted-by":"crossref","unstructured":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348:1049\u201354.","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"3566_CR7","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","volume":"30","author":"D Peiffert","year":"2012","unstructured":"Peiffert D, Tournier-Rangeard L, G\u00e9rard J-P, Lemanski C, Fran\u00e7ois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941\u20138.","journal-title":"J Clin Oncol"},{"key":"3566_CR8","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent Chemoradiation involving fluorouracil\/Mitomycin versus fluorouracil\/Cisplatin. J Clin Oncol. 2012;30:4344\u201351.","journal-title":"J Clin Oncol"},{"key":"3566_CR9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2x2 factorial trial. Lancet Oncol. 2013;14:516\u201324.","journal-title":"Lancet Oncol."},{"key":"3566_CR10","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/cncr.25188","volume":"116","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB III, Thomas CR Jr, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer. Cancer. 2010;116:4007\u201313.","journal-title":"Cancer"},{"key":"3566_CR11","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","volume":"40","author":"R Glynne-Jones","year":"2014","unstructured":"Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. EJSO. 2014;40:1165\u201376.","journal-title":"EJSO"},{"key":"3566_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/756591","volume":"2012","author":"A Dewdney","year":"2012","unstructured":"Dewdney A, Rao S. Metastatic Squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? ISRN Oncology. 2012;2012:1\u20136.","journal-title":"ISRN Oncology"},{"key":"3566_CR13","first-page":"861","volume":"86","author":"C Faivre","year":"1999","unstructured":"Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, et al. Carcinome \u00e9pidermo\u00efde m\u00e9tastatique de l\u2019anus : \u00e9tude r\u00e9trospective de l\u2019efficacit\u00e9 de l\u2019association de 5-fluoro-uracile en perfusion continue et de cisplatine. Bull Cancer. 1999;86:861\u20135.","journal-title":"Bull Cancer"},{"key":"3566_CR14","unstructured":"Benson AB III, Venook AP, Bekail-Saab T, Chan E, Chen Y-J. Analcarcinoma, version2. 2016: featured updates to the NCCN guidelines. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf . Accessed 7 May 2016."},{"key":"3566_CR15","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"299","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914\u201321.","journal-title":"JAMA"},{"key":"3566_CR16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0196-72","volume":"2","author":"AF Wahl","year":"1996","unstructured":"Wahl AF, Donaldson KL, Faircnild C, Lee FYF, Foster SA, Demers GW, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2\/M arrest and apoptosis. Nat Med. 1996;2:72\u20139.","journal-title":"Nat Med"},{"key":"3566_CR17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","volume":"63","author":"M Scheffner","year":"1990","unstructured":"Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129\u201336.","journal-title":"Cell"},{"key":"3566_CR18","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1126\/science.1224922","volume":"337","author":"L Senovilla","year":"2012","unstructured":"Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337:1678\u201384.","journal-title":"Science"},{"key":"3566_CR19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(10)70279-5","volume":"12","author":"JH Lorch","year":"2011","unstructured":"Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12:153\u20139.","journal-title":"Lancet Oncol"},{"key":"3566_CR20","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mdt396","volume":"24","author":"S Kim","year":"2013","unstructured":"Kim S, Jary M, Mansi L, Benzidane B, Cazorla A, Demarchi M, et al. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol. 2013;24:3045\u201350.","journal-title":"Ann Oncol"},{"key":"3566_CR21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","volume":"39","author":"L Zitvogel","year":"2013","unstructured":"Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39:74\u201388.","journal-title":"Immunity"},{"key":"3566_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1\u201310.","journal-title":"Control Clin Trials"},{"key":"3566_CR23","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-05-2647","volume":"12","author":"O Adotevi","year":"2006","unstructured":"Adotevi O. Immunogenic HLA-B*0702-restricted Epitopes derived from human telomerase reverse transcriptase that elicit antitumor Cytotoxic T-cell responses. Clin Cancer Res. 2006;12:3158\u201367.","journal-title":"Clin Cancer Res"},{"key":"3566_CR24","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/1078-0432.CCR-11-3185","volume":"18","author":"Y Godet","year":"2012","unstructured":"Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res. 2012;18:2943\u201353.","journal-title":"Clin Cancer Res"},{"key":"3566_CR25","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ejca.2010.07.023","volume":"46","author":"F Bonnetain","year":"2010","unstructured":"Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer. 2010;46:2753\u201362.","journal-title":"Eur J Cancer"},{"key":"3566_CR26","first-page":"4637","volume":"3112","author":"A Abbas","year":"2011","unstructured":"Abbas A, Nehme E, Fakih M. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Anticancer Res. 2011;3112:4637\u201340.","journal-title":"Anticancer Res."},{"key":"3566_CR27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00384-008-0467-3","volume":"237","author":"T Alcindor","year":"2008","unstructured":"Alcindor T. Activity of paclitaxel in metastatic squamous anal carcinoma. Int J Colorectal Dis. 2008;237:717.","journal-title":"Int J Colorectal Dis."},{"key":"3566_CR28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/1097-0142(20010801)92:3<642::AID-CNCR1365>3.0.CO;2-Z","volume":"923","author":"JD Hainsworth","year":"2001","unstructured":"Hainsworth JD, Burris HA, III, Meluch AA, et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a phase II trial. Cancer. 2001;923:642\u20139.","journal-title":"Cancer."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3566-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T16:29:15Z","timestamp":1570033755000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3566-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3566"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3566-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,25]]},"article-number":"574"}}